Payment overview · 2025
General Payments
$181.40
10 reported records · 6 companies
Healthcare provider profile · identity verified
Marty Wayne Odom, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLARKSVILLE, TN · NPI 1265520662
Verified facts
What the public records show
CMS Open Payments records show Marty Wayne Odom, MD received $181.40 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.24 | 29.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.91 | 28.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.16 | 13.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.92 | 11.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.17 | 9.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.00 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $181.40 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.24 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.24 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.91 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
140 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 712 | 174 |
| Omeprazole | Omeprazole | 524 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 413 | 99 |
| Losartan Potassium | Losartan Potassium | 402 | 113 |
| Lisinopril | Lisinopril | 375 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 56 |
| Potassium Chloride | Potassium Chloride | 220 | 64 |
| Methylprednisolone | Methylprednisolone | 209 | 155 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 44 |
| Carvedilol | Carvedilol | 186 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 42 |
| Furosemide | Furosemide | 175 | 42 |
| Montelukast Sodium | Montelukast Sodium | 170 | 49 |
| Simvastatin | Simvastatin | 149 | 42 |
| Azithromycin | Azithromycin | 143 | 115 |
| Gabapentin | Gabapentin | 142 | 25 |
| Farxiga | Dapagliflozin Propanediol | 140 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 49 |
| Glipizide Er | Glipizide | 127 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 126 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 29 |
| Metformin Hcl | Metformin Hcl | 111 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 21 |
| Warfarin Sodium | Warfarin Sodium | 102 | 13 |
| Ezetimibe | Ezetimibe | 101 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 94 | 78 |
| Eliquis | Apixaban | 94 | 25 |
| Famotidine | Famotidine | 92 | 32 |
| Meloxicam | Meloxicam | 90 | 22 |
| Spironolactone | Spironolactone | 88 | 25 |
| Buspirone Hcl | Buspirone Hcl | 87 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 21 |
| Sucralfate | Sucralfate | 84 | 23 |
| Celecoxib | Celecoxib | 82 | 27 |
| Alprazolam | Alprazolam | 81 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 20 |
| Finasteride | Finasteride | 79 | 25 |
| Sertraline Hcl | Sertraline Hcl | 79 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 77 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 19 |
| Trazodone Hcl | Trazodone Hcl | 75 | 25 |
| Prednisone | Prednisone | 73 | 60 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 16 |
| Enalapril Maleate | Enalapril Maleate | 72 | 16 |
| Allopurinol | Allopurinol | 70 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 21 |
| Lovastatin | Lovastatin | 63 | 15 |
| Ozempic | Semaglutide | 55 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 17 |
| Jardiance | Empagliflozin | 54 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 35 |
| Donepezil Hcl | Donepezil Hcl | 43 | 12 |
| Ondansetron Odt | Ondansetron | 42 | 29 |
| Levofloxacin | Levofloxacin | 41 | 31 |
| Tramadol Hcl | Tramadol Hcl | 40 | 17 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 12 |
| Metformin Hcl Er | Metformin Hcl | 36 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Klor-Con M20 | Potassium Chloride | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 25 |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Gemtesa | Vibegron | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $181.40 · 10 records | Lilly USA, LLC | BREZTRI, Dexcom G6 Transmitter, GVOKE HYPOPEN, INSPIRE, MOUNJARO, OTEZLA, REPATHA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error